<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30117">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01928017</url>
  </required_header>
  <id_info>
    <org_study_id>2011/1881</org_study_id>
    <nct_id>NCT01928017</nct_id>
  </id_info>
  <brief_title>Thromboelastography, Cytokines and HLA-antibodies in Patients With Chemotherapy-induced Thrombocytopenia</brief_title>
  <official_title>Thromboelastography, Cytokines and HLA-antibodies in Patients With Chemotherapy-induced Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <authority>Norway: Regional Ethics Commitee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational clinical study to characterise abnormalities of
      thromboelastography (TEG) parameters in patients with chemotherapy-induced thrombocytopenia.
      The investigators are also studying the influence of cytokines on bleeding and of
      HLA-antibodies on effect of platelet transfusion in the patient group mentioned.

      The investigators' hypothesis is that changes in TEG-parameters reflect the patients
      tendency to bleed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Thromboelastography</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise changes in TEG-parameters in patients with chemotherapy-induced thrombocytopenia</description>
  </primary_outcome>
  <other_outcome>
    <measure>Cytokines</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To investigate cytokine profiles in patients with and without bleeding with the aim of identifying risk factors of bleeding in patients with chemotherapy-induced thrombocytopenia</description>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To investigate the relationship between TEG-parameters, bleeding and need for platelet transfusion.
To investigate the influence of HLA antibodies on risk of bleeding and transfusion complications.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bone Marrow Diseases</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Hematooncology patients</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma specimens are kept frozen.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital inpatients admitted to the Department of Medicine, Section for Haematology at
        Haukeland University Hospital will be invited to join the study if they meet the inclusion
        criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are eligible for this study if:

          -  They have chemotherapy-induced thrombocytopenia

          -  They are in need of at least one platelet transfusion

          -  They are aged 16 years or over

          -  They consent to participate

        Exclusion Criteria:

        Patients are not eligible for this study if:

          -  They have a known congenital clotting disorder

          -  They need anticoagulants regularly in the study period

          -  They have immune thrombocytopenic purpura
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tor A Hervig, dr.med</last_name>
    <role>Study Director</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elin N Opheim, cand.med.</last_name>
    <phone>004755973044</phone>
    <email>elin.opheim@k2.uib.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tor A Hervig, dr.med</last_name>
    <phone>004755972492</phone>
    <email>tor.hervig@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elin N Opheim, cand.med</last_name>
      <phone>004755973044</phone>
      <email>elin.opheim@k2.uib.no</email>
    </contact>
    <contact_backup>
      <last_name>Torunn O Apelseth, dr. med</last_name>
      <phone>004755973092</phone>
      <email>torunn.oveland.apelseth@helse-bergen.no</email>
    </contact_backup>
    <investigator>
      <last_name>Elin N Opheim, cand.med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 20, 2013</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bergen</investigator_affiliation>
    <investigator_full_name>Elin Netland Opheim</investigator_full_name>
    <investigator_title>Research fellow</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
